Pharmacists in Loiza, PR Accepting Medicare
6 Pharmacists found. Showing 1 - 6
 Mrs. Irma Nydia Alvarez, PHD Pharmacist Medicare: Not Enrolled in Medicare Practice Location: Carretera #188 Imt #187, Loiza, PR 00772 Phone: 787-876-2042 Fax: 787-256-1900 |
Abigail Oquendo, BS Pharmacist Medicare: Not Enrolled in Medicare Practice Location: Carr 187 Km 7.0 Mediania Alta, Loiza, PR 00772 Phone: 787-876-1927 |
 Santiago Molina Pharmacist Medicare: Not Enrolled in Medicare Practice Location: Farmacia Mediania 187, Box 528, Loiza, PR 00772 Phone: 787-876-1927 Fax: 787-876-1927 |
Amalis Yudith Hernandez Cabrera Pharmacist Medicare: Not Enrolled in Medicare Practice Location: Calle 1, Lote B-1, Urb. Villas De Loiza, 300 Calle 1, Canovanas, Loiza, Loiza, PR 00729 Phone: 787-876-3500 |
Gloria M. Osorio Pharmacist Medicare: Not Enrolled in Medicare Practice Location: Urb. Jardines De Loiza, C-41 Calle 3, Loiza, PR 00772 Phone: 787-876-5157 |
Carmen R Fernandez, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: Carretera 187 Km 7.0 Mediania Alta, Loiza, PR 00772 Phone: 787-876-1927 Fax: 787-256-2777 |
News Archive
Offers from Eppendorf Advantage to improve laboratory efficiency
For researchers and technicians requiring the highest levels of confidence, accuracy, and reliability, the latest Eppendorf Advantage™ offers provide premium solutions for greater laboratory efficiency. Customers can benefit from savings of up to 30% off selected products, until December 2015. In line with their renowned expertise, Eppendorf continues to provide the high-quality solutions for cell biology processes.
RMEI and PIM sponsor education webcast on therapeutic considerations for CRPC
Castrate-refractory prostate cancer (CRPC), which is characterized by tumor progression despite castrate levels of testosterone, develops in many prostate cancer patients treated with androgen-deprivation therapy. Standardized guidelines for treatment of CRPC are lacking and healthcare professionals must consider several factors, including serum markers, patient age and pre-existing comorbidities when choosing between second-line hormonal therapy and chemotherapy for treatment of CRPC.
NMQF launches the P.A.D. Atlas database that maps peripheral arterial disease prevalence by zip code
The National Minority Quality Forum (NMQF), one of the nation's leading voices in the health disparities discussion, is launching the P.A.D. Atlas, a database that maps by zip code peripheral arterial disease (P.A.D.) prevalence down to the street level, with the P.A.D. Coalition and support from the Bristol-Myers Squibb/Sanofi Pharmaceuticals Partnership.
HDL in CAD patients different from HDL in healthy individuals
High levels of "good" cholesterol (HDL cholesterol) are associated with a decreased risk of coronary artery disease (CAD) - a disease of the major arterial blood vessels that is one of the major causes of heart attack and stroke. This suggests that therapeutics that increase HDL levels could be clinically useful.
› Verified 9 days ago